Production of oligodendrocytes from placenta-derived stem cells

Abstract

The present invention provides methods and compositions for the production of glial cells and oligodendrocytes from placenta stem cells. The invention further provides for the use of these glia and oligodendrocytes in the treatment of, and intervention in, for example, trauma, ischemia and degenerative disorders of the central nervous system (CNS), particularly in the treatment of demyelinating diseases such as multiple sclerosis.

1 . A method of producing an oligodendrocyte, comprising culturing a placenta-derived stem cell under conditions and for a time sufficient for said stem cell to exhibit a characteristic of an oligodendrocyte. 
     
     
         2 . The method of  claim 1 , wherein said characteristic is the production of myelin oligodendrocyte specific protein or expression of a gene encoding myelin oligodendrocyte specific protein. 
     
     
         3 . The method of  claim 1 , wherein said culturing comprises contacting said stem cell with isobutylmethylxanthine (IBMX). 
     
     
         4 . An oligodendrocyte produced by the method of  claim 1 . 
     
     
         5 . A method of treating a subject having a disease, disorder or condition associated with abnormal myelination, comprising introducing the oligodendrocyte of  claim 4  to said subject. 
     
     
         6 . The method of  claim 5 , wherein said disease, disorder or condition is multiple sclerosis.